Stockreport

AVEO Oncology Announces Lancet Oncology Publication of Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma

AVEO Pharmaceuticals, Inc.  (AVEO) 
Last aveo pharmaceuticals, inc. earnings: 3/16 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.aveooncology.com
PDF CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) today announced that previously reported data from its Phase 3 TIVO-3 study were published in The Lan [Read more]